Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report

被引:13
作者
Zamora, Natalia V. [1 ,6 ]
Christensen, Robin [6 ]
Goel, Niti [2 ,3 ,8 ]
Klokker, Louise [6 ]
Lopez-Olivo, Maria A. [1 ]
Kristensen, Lars E. [6 ]
Carmona, Loreto [7 ]
Strand, Vibeke [4 ]
Curtis, Jeffrey R. [5 ]
Suarez-Almazor, Maria E. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Sect Rheumatol & Clin Immunol, Houston, TX 77030 USA
[2] Quintiles IMS, Advisory Serv, Durham, NC USA
[3] Duke Univ, Sch Med, Div Rheumatol, Durham, NC USA
[4] Stanford Univ, Div Rheumatol & Immunol, Palo Alto, CA 94304 USA
[5] Univ Alabama Birmingham, Div Clin Immunol & Rheumatol, Birmingham, AL 35294 USA
[6] Bispebjerg & Frederiksberg Hosp, Parker Inst, Musculoskeletal Stat Unit, Copenhagen, Denmark
[7] Inst Salud Musculoesquelet, Madrid, Spain
[8] Duke Univ, Sch Med, Quintiles IMS, Advisory Serv, Durham, NC USA
关键词
OBSERVATIONAL STUDIES; REGISTRIES; RHEUMATOID ARTHRITIS; OUTCOME ASSESSMENT; OMERACT; CLINICAL-TRIALS; CORE SETS; REGISTERS; POINTS;
D O I
10.3899/jrheum.161108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective. Outcomes important to patients are those that are relevant to their well-being, including quality of life, morbid endpoints, and death. These outcomes often occur over the longterm and can be identified in prospective longitudinal observational studies (PLOS). There are no standards for which outcome domains should be considered. Our overarching goal is to identify critical longterm outcome domains for patients with rheumatic diseases, and to develop a conceptual framework to measure and classify them within the scope of OMERACT Filter 2.0. Methods. The steps of this initiative primarily concern rheumatoid arthritis (RA) and include (1) performing a systematic review of RA patient registries and cohorts to identify previously collected and reported outcome domains and measurement instruments; (2) developing a conceptual framework and taxonomy for identification and classification of outcome domains; (3) conducting focus groups to identify domains considered critical by patients with RA; and (4) surveying patients, providers, and researchers to identify critical outcomes that can be evaluated through the OMERACT filter. Results. In our initial evaluation of databases and registries across countries, we found both commonalities and differences, with no clear standardization. At the initial group meeting, participants agreed that additional work is needed to identify which critical outcomes should be collected in PLOS, and suggested several: death, independence, and participation, among others. An operational strategy for the next 2 years was proposed. Conclusion. Participants endorsed the need for an initiative to identify and evaluate critical outcome domains and measurement instruments for data collection in PLOS.
引用
收藏
页码:1894 / 1898
页数:5
相关论文
共 19 条
[1]  
Agency for Healthcare Research and Quality, 2016, OUTC MEAS FRAM LIT R
[2]  
Bellamy N, 1997, J RHEUMATOL, V24, P799
[3]  
BOERS M, 1994, J RHEUMATOL, V21, P86
[4]   Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0 [J].
Boers, Maarten ;
Kirwan, John R. ;
Wells, George ;
Beaton, Dorcas ;
Gossec, Laure ;
d'Agostino, Maria-Antonietta ;
Conaghan, Philip G. ;
Bingham, Clifton O., III ;
Brooks, Peter ;
Landewe, Robert ;
March, Lyn ;
Simon, Lee S. ;
Singh, Jasvinder A. ;
Strand, Vibeke ;
Tugwell, Peter .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2014, 67 (07) :745-753
[5]   Databases and registers: useful tools for research, no studies [J].
Curbelo, Rafael J. ;
Loza, Estibaliz ;
Garcia de Yebenes, Maria Jesus ;
Carmona, Loreto .
RHEUMATOLOGY INTERNATIONAL, 2014, 34 (04) :447-452
[6]   A Comparison of Patient Characteristics and Outcomes in Selected European and US Rheumatoid Arthritis Registries [J].
Curtis, Jeffrey R. ;
Jain, Archana ;
Askling, Johan ;
Bridges, S. Louis, Jr. ;
Carmona, Loreto ;
Dixon, William ;
Finckh, Axel ;
Hyrich, Kimme ;
Greenberg, Jeffrey D. ;
Kremer, Joel ;
Listing, Joachim ;
Michaud, Kaleb ;
Mikuls, Ted ;
Shadick, Nancy ;
Solomon, Daniel H. ;
Weinblatt, Michael E. ;
Wolfe, Fred ;
Zink, Angela .
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2010, 40 (01) :2-14
[7]   EULAR points to consider when establishing, analysing and reporting safety data of biologics registers in rheumatology [J].
Dixon, William G. ;
Carmona, Loreto ;
Finckh, Axel ;
Hetland, Merete Lund ;
Kvien, Tore K. ;
Landewe, Robert ;
Listing, Joachim ;
Nicola, Paulo J. ;
Tarp, Ulrik ;
Zink, Angela ;
Askling, Johan .
ANNALS OF THE RHEUMATIC DISEASES, 2010, 69 (09) :1596-1602
[8]   Relative importance of doctor-reported outcomes vs patient-reported outcomes in DMARD intensification for rheumatoid arthritis: the DUO study [J].
Dougados, Maxime ;
Nataf, Henri ;
Steinberg, Ghislaine ;
Rouanet, Stephanie ;
Falissard, Bruno .
RHEUMATOLOGY, 2013, 52 (02) :391-399
[9]   Registries for Robust Evidence [J].
Dreyer, Nancy A. ;
Garner, Sarah .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2009, 302 (07) :790-791
[10]   Examining the Similarities and Differences of OMERACT Core Sets Using the ICF: First Step Towards an Improved Domain Specification and Development of an Item Pool to Measure Functioning and Health [J].
Escorpizo, Reuben ;
Boers, Maarten ;
Stucki, Gerold ;
Boonen, Annelies .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (08) :1739-1744